HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Calder, P. C Search for Related Content PubMed PubMed Citation Articles by Calder, P. C Agricola Articles by Calder, P. C

n–3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases^1,2,3

¹ From the Institute of Human Nutrition, School of Medicine, University of Southampton, Southampton, United Kingdom

ABSTRACT

Inflammation is part of the normal host response to infection and injury. However, excessive or inappropriate inflammation contributes to a range of acute and chronic human diseases and is characterized by the production of inflammatory cytokines, arachidonic acid–derived eicosanoids (prostaglandins, thromboxanes, leukotrienes, and other oxidized derivatives), other inflammatory agents (eg, reactive oxygen species), and adhesion molecules. At sufficiently high intakes, long-chain n–3 polyunsaturated fatty acids (PUFAs), as found in oily fish and fish oils, decrease the production of inflammatory eicosanoids, cytokines, and reactive oxygen species and the expression of adhesion molecules. Long-chain n–3 PUFAs act both directly (eg, by replacing arachidonic acid as an eicosanoid substrate and inhibiting arachidonic acid metabolism) and indirectly (eg, by altering the expression of inflammatory genes through effects on transcription factor activation). Long-chain n–3 PUFAs also give rise to a family of antiinflammatory mediators termed resolvins. Thus, n–3 PUFAs are potentially potent antiinflammatory agents. As such, they may be of therapeutic use in a variety of acute and chronic inflammatory settings. Evidence of their clinical efficacy is reasonably strong in some settings (eg, in rheumatoid arthritis) but is weak in others (eg, in inflammatory bowel diseases and asthma). More, better designed, and larger trials are required to assess the therapeutic potential of long-chain n–3 PUFAs in inflammatory diseases. The precursor n–3 PUFA -linolenic acid does not appear to exert antiinflammatory effects at achievable intakes.

Key Words: Inflammation • monocyte • macrophage • eicosanoid • cytokine • inflammatory disease

This article has been cited by other articles:

				N.-T. Luu, J. Madden, P. C. Calder, R. F. Grimble, C. P. Shearman, T. Chan, N. Dastur, W. M. Howell, G. E. Rainger, and G. B. Nash Dietary Supplementation with Fish Oil Modifies the Ability of Human Monocytes to Induce an Inflammatory Response J. Nutr., December 1, 2007; 137(12): 2769 - 2774. [Abstract] [Full Text] [PDF]

				H. Yin, J. D. Brooks, L. Gao, N. A. Porter, and J. D. Morrow Identification of Novel Autoxidation Products of the {omega}-3 Fatty Acid Eicosapentaenoic Acid in Vitro and in Vivo J. Biol. Chem., October 12, 2007; 282(41): 29890 - 29901. [Abstract] [Full Text] [PDF]

				S. R. Shaikh and M. Edidin Polyunsaturated fatty acids, membrane organization, T cells, and antigen presentation Am. J. Clinical Nutrition, December 1, 2006; 84(6): 1277 - 1289. [Abstract] [Full Text] [PDF]